Meeting registration

Meeting objectives & introduction
Naval Daver

Session 1: Updates on established therapies in AML – Part 1
Chairs: Andrew Wei & Eytan Stein

• IC+VEN in newly diagnosed fit AML – current status and patient selection: Tapan Kadia
• Deciphering the biological basis of the GVL effect: Paresh Vyas
• Optimizing transplant outcomes in AML and role of maintenance post ASCT: Charles Craddock
• Role and optimal maintenance strategies in AML patients not going to ASCT: Maximilian Stahl
• CPX updates & new data: Tara Lin

Panel Discussion

Session 2: Translational and lab developments and applications in AML
Chairs: Ravi Majeti & Paresh Vyas

• Antigen targets and novel CAR-T strategies: Ravi Majeti
• Approaches to leverage single-cell sequencing in understanding AML biology and response to therapy: Koichi Takahashi
• Potential for early intervention in CHIP and CCUS: Uma Borate
• Designing and applying a FLT3 like signature in AML: Adrián Mosquera Orgueira
• Ancestry-inclusive consideration of AML genomics: Ann-Kathrin Eisfeld

Panel discussion

Welcome reception

Session 3: Updates on established therapies in AML – Part 2
Chairs: Naval Daver & Charles Craddock

• Optimal approach to treatment of secondary/therapy related AML: Jorge Cortes
• IDHm impacts treatment of younger adults with AML: Courtney DiNardo
• Frontline approaches for FLT3-mutant AML: Naval Daver
• Current approaches and challenges for relapsed FLT3-mutant AML: Alexander Perl

Panel discussion

Session 4: International trials group
Chairs: Courtney DiNardo & Paresh Vyas

• HOVON: Paresh Vyas
• MDACC: Naval Daver
• UK trials: Charles Craddock
• Australian trials: Andrew Wei
• French trials: Stéphane de Botton
• myeloMATCH: Richard Little

Panel discussion

Break

Session 5: IC vs HMA+VEN for all non-FLT3 mutated patients >60 years of age regardless of physical fitness
Chairs: Mark Levis and Jessica Altman

Pro: Eunice Wang and Tapan Kadia – in favour of HMA+ VEN

Con: Harry Erba and Stéphane de Botton – in favour of IC

Lunch

Session 6: New frontiers in MRD for AML clinical practice
Chairs: Stéphane de Botton & Gail Roboz

• Single-cell sequencing and clinical applicability in detection and therapy of AML: Catherine Smith
• MRD as a clinical endpoint in clinical trials: Nicholas Short
• Applying MRD techniques in FLT3-mutated AML – are we able to use MRD as an endpoint?: Christopher Hourigan

Panel discussion

Session 7: BPDCN & MDS/MPN + CMML
Chairs: Marina Konopleva & Mrinal Patnaik

• Updates in diagnosis, pathogenesis, and future directions in BPDCN: Marina Konopleva
• VEXAS syndrome: Emma Groarke
• Future targets and drug development in CMML: Mrinal Patnaik
• AP/BP MPN to post-MPN AML: Anand Patel

Panel discussion

Break

Session 8: Transplant and immunotherapies in AML
Chairs: Charles Craddock & Roland Walter

• Vedolizumab for prophylaxis and treatment of acute GvHD post-alloSCT: Yngvar Fløisand
• Which patients with AML in MRD+ remission should be transplanted?: Roland Walter
• Early phase CAR-T and NK cell trials for R/R AML and MDS: Nelli Bejanyan
• NK cell-based therapies in AML: Jeffrey Miller

Panel discussion

Session 9: Special session on regulatory endpoints in AML
Chairs:  Naval Daver & Courtney DiNardo

• The FDA’s perspective on regulatory endpoints in AML: Kelly Norsworthy
• A clinical investigator’s perspective on drug development and endpoints: Gail Roboz

Panel discussion

Day 1 wrap-up

Faculty Dinner

Introduction to Day 3

Session 10: Menin inhibition
Chairs: Naval Daver & Jessica Altman                                                                                              

• Single-agent menin inhibitors – efficacy, biomarkers and resistance: Eunice Wang
• Updates on menin inhibitor-based combination in AML: Ghayas Issa
• Frontline triplets with menin inhibitors in AML: Joshua Zeidner
  Panel discussion

Session 11: Novel targets, combinations and treatments in AML Part 1 – new AML therapies and limitations
Chairs: Richard Stone & Marina Konopleva

• Overcoming resistance to venetoclax-based therapies in AML: Marina Konopleva
• Uproleselan in frontline and R/R AML: Daniel DeAngelo
• Promising combination options in AZA/VEN for R/R AML: Thomas Cluzeau
  Panel discussion

Break

Session 12: Novel targets, combinations and treatments in AML Part 2
Chairs: Tapan Kadia & Eunice Wang

• TP53 treatment strategies in AML – how do we crack this nut?: David Sallman
• Tuspetinib for relapsed or refractory AML: Gabriel Mannis
• How best to use Plerixafor for our AML patients?: Geoffrey Uy

Panel discussion

Session 13: Novel targets, combinations and treatments in AML Part 3
Chairs: Farhad Ravandi & Catherine Smith

• Optimal use of OGM and RNA-translocation panel in frontline AML: Sanam Loghavi
• Novel ADCs in AML – how best to incorporate and use them: Farhad Ravandi
• Leveraging STING for therapeutic benefit in AML: Andrew Wei

 

Meeting concludes, followed by lunch